Delisting of Q-Med AB (publ)

NASDAQ OMX Stockholm has decided that Q-Med AB (publ) will be delisted from
NASDAQ OMX Stockholm. The last trading day of the shares will be Friday, March
25, 2011.
As a consequence of the delisting of the share, Q-Med has decided not to
announce the company's quarterly report for January - March 2011.


Uppsala March 11, 2011
The Board of Q-Med AB (publ)


Queries should be addressed to:
Carina Bolin, CEO & General Counsel
Telephone: +46 70 974 9117
Alexander Kotsinas, CFO
Telephone: +46 73 500 111


The information in this press release is such as that which Q-Med is required to
disclose in accordance with the Swedish Securities Market Act and/or the
Financial Instruments Trading Act. The information was submitted for disclosure
at 7.30 a.m. on March 11, 2011.


Q-Med AB is a medical device company that develops, manufactures, markets, and
sells high quality medical implants for esthetic and medical use. The majority
of the products are based on the company's patented technology, NASHA(TM), for
the production of stabilized non-animal hyaluronic acid. The product portfolio
today contains: Restylane® for filling lines and folds, contouring and creating
volume in the face, Macrolane(TM) for body contouring, Durolane(TM) for the
treatment of osteoarthritis of the hip and knee joints, Deflux® for the
treatment of vesicoureteral reflux, VUR, (a malformation of the urinary bladder)
in children, and Solesta® for the treatment of fecal incontinence. Sales are
made through the company's own subsidiaries or distributors in over 70
countries. Q-Med has about 650 coworkers, with almost 400 at the company's head
office and production facility in Uppsala, Sweden. Q-Med AB is listed in the Mid
Cap segment of the NASDAQ OMX Nordic.


Q-Med AB (publ), Seminariegatan 21, SE-752 28 Uppsala, Sweden. Corporate
identity number 556258-6882.
Tel: +46 18 474 90 00. Fax: +46 18 474 90 01. E-mail:info@q-med.com. Web: www.q-
med.com

[HUG#1496239]